A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice
Kangli Cao, Xiang Wang, Haoran Peng, Longfei Ding, Xiangwei Wang, Yangyang Hu, Lanlan Dong, Tianhan Yang, Xiujing Hong, Man Xing, Duoduo Li, Cuisong Zhu, Xiangchuan He, Chen Zhao, Ping Zhao, Dongming Zhou, Xiaoyan Zhang, Jianqing Xu
Abstract
The COVID-19 pandemic exemplifies the severe public health threats of respiratory virus infection and influenza A viruses. The currently envisioned strategy for the prevention of respiratory virus-causing diseases requires the comprehensive administration of vaccines tailored for individual viruses. Here, we present an alternative strategy by designing chimpanzee adenovirus 68-based vaccines which target both the SARS-CoV-2 receptor-binding-domain and the conserved stalk of influenza hemagglutinin. When tested in mice, this strategy attained potent neutralizing antibodies against wild-type SARS-CoV-2 and its emerging variants, enabling an effective protection against lethal SARS-CoV-2 challenge. Notably, it also provided complete protection from lethal H7N9 challenge and efficient control of H3N2-induced morbidity. Our study opens a new avenue to universally curb respiratory virus infection by vaccination.